会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • 2-Aminoalcohols for the Treatment of Neurodegenerative Diseases
    • 用于治疗神经退行性疾病的2-氨基醇
    • US20090192229A1
    • 2009-07-30
    • US12066904
    • 2006-09-21
    • Robin Mark BannisterMichael Harvey Lyne
    • Robin Mark BannisterMichael Harvey Lyne
    • A61K31/133A61P25/00
    • A61K31/137Y10S514/903
    • Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is part of a ring with R5; R5 is aryl or heteroaryi optionally substituted with R7; each R6 is independently alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, SO2NH2, Salkyl, CH2SO2alkyl or OCONalkyl2; R7 is R8 or (CH2)nOR8, R9, CF3, OH, OR9, OCOR9, COR9, COOR9, CONH2, CH2CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHCONHR7, NHCON(R9)2, NHCOR9, NHCOaryl, NHSO2Me, CONH2, SMe, SOMe or SO2NH2; R8 is (CH2)nOR9, (CH)nOR9, (CH2)nCOOR9 or (CH2)nCOaryl; R9 is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.
    • 用于制备用于治疗神经变性病症的药物的化合物的用途,其中所述化合物为式(I):其中R 1为CHR 4 -OR 5或CHR 4 -SR 5,或任选被一个或多个取代基取代的芳基或杂芳基 R6组; R2是烷基或是与R3的环的一部分; R3是H,烷基或CH2(当与R2形成环的一部分时); R4是H或烷基,或是与R5的环的一部分; R 5是任选被R 7取代的芳基或杂芳基; 每个R 6独立地是烷基,CF 3,OH,O烷基,OCO烷基,CONH 2,CN,卤素,NH 2,NO 2,NHCHO,NHCONH 2,NHSO 2烷基,CONH 2,SOMe,SO 2 NH 2,S烷基,CH 2 SO 2烷基或OCON烷基2; R 7是R 8或(CH 2)nOR 8,R 9,CF 3,OH,OR 9,OCOR 9,COR 9,COOR 9,CONH 2,CH 2 CONH 2,CN,卤素,NH 2,NO 2,NHCHO,NHCONH 2,NHCONHR 7,NHCON(R 9)2,NHCOR 9, ,NHSO2Me,CONH2,SMe,SOMe或SO2NH2; R8是(CH2)nOR9,(CH)nOR9,(CH2)nCOOR9或(CH2)nCOaryl; R9是烷基或环烷基; n为1〜4; 或其盐。
    • 4. 发明授权
    • 2-aminoalcohols for the treatment of neurodegenerative diseases
    • 2-氨基醇用于治疗神经变性疾病
    • US08188152B2
    • 2012-05-29
    • US12066904
    • 2006-09-21
    • Robin Mark BannisterMichael Harvey Lyne
    • Robin Mark BannisterMichael Harvey Lyne
    • A01N27/00
    • A61K31/137Y10S514/903
    • Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is part of a ring with R 5; R5 is aryl or heteroaryi optionally substituted with R7; each R6 is independently alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, SO2NH2, Salkyl, CH2SO2alkyl or OCONalkyl2; R7 is R8 or (CH2)nOR8, R9, CF3, OH, OR9, OCOR9, COR9, COOR9, CONH2, CH2CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHCONHR7, NHCON(R9)2, NHCOR9, NHCOaryl, NHSO2Me, CONH2, SMe, SOMe or SO2NH2; R8 is (CH2)nOR9, (CH)nOR9, (CH2)nCOOR9 or (CH2)nCOaryl; R9 is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.
    • 用于制备用于治疗神经变性病症的药物的化合物的用途,其中所述化合物为式(I):其中R 1为CHR 4 -OR 5或CHR 4 -SR 5,或任选被一个或多个取代基取代的芳基或杂芳基 R6组; R2是烷基或是与R3的环的一部分; R3是H,烷基或CH2(当与R2形成环的一部分时); R 4为H或烷基,或为R 5的环的一部分; R 5是任选被R 7取代的芳基或杂芳基; 每个R 6独立地是烷基,CF 3,OH,O烷基,OCO烷基,CONH 2,CN,卤素,NH 2,NO 2,NHCHO,NHCONH 2,NHSO 2烷基,CONH 2,SOMe,SO 2 NH 2,S烷基,CH 2 SO 2烷基或OCON烷基2; R 7是R 8或(CH 2)nOR 8,R 9,CF 3,OH,OR 9,OCOR 9,COR 9,COOR 9,CONH 2,CH 2 CONH 2,CN,卤素,NH 2,NO 2,NHCHO,NHCONH 2,NHCONHR 7,NHCON(R 9)2,NHCOR 9, ,NHSO2Me,CONH2,SMe,SOMe或SO2NH2; R8是(CH2)nOR9,(CH)nOR9,(CH2)nCOOR9或(CH2)nCOaryl; R9是烷基或环烷基; n为1〜4; 或其盐。